Trial Profile
A phase I trial of single, ascending doses of DRL 17822 in healthy volunteers.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 09 Apr 2020
Price :
$35
*
At a glance
- Drugs DRL 17822 (Primary)
- Indications Atherosclerosis; Chronic obstructive pulmonary disease; Dyslipidaemias; Lipid metabolism disorders
- Focus Adverse reactions; First in man
- Sponsors Dr Reddys Laboratories
- 06 Apr 2020 Results from four phase 1 studies: study 1: first-in-human single dose phase, study 2: single dose food interaction study, study 3: two-week once daily multiple dose study and study 4: (part A and B) was a single dose food and formulation interaction study on the population pharmacokinetics of DRL-17822 in healthy male volunteers were published in the British Journal of Clinical Pharmacology
- 29 Jun 2010 Results were reported at the 70th Annual Scientific Sessions of the American Diabetes Association.
- 25 Jun 2010 Status changed from recruiting to completed.